Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787787 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00787787 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 41 participants.
The verdict
NCT00787787, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib malate together with capecitabine may kill more tumor cells
Interventions
- DRUG capecitabine
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787787
The ClinicalTrials.gov registry entry for NCT00787787 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which capecitabine is the first listed.
NCT00787787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787787 about?
NCT00787787 is a clinical study titled "Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer". This phase II trial studies how well giving sunitinib malate together with capecitabine works in treating patients with unresectable or metastatic liver cancer. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to th...
What is the current status of trial NCT00787787?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2008-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00787787?
The interventions under investigation include: capecitabine (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00787787?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.